Larvol Delta - ABLi-Therapeuticsannounces-publication-of-the-nal-trial-results-from-the-Phase-2-39201-Trial39-NCT05424276-evaluating-risvodetinib-in-patients-with-untreated-Parkinsons-disease-PD

risvodetinib (ABLi-148009) - ABLi Therapeutics

https://www.globenewswire.com/news-release/2026/02/20/3241902/0/en/ABLi-Therapeutics-Announces-Publication-of-the-Final-Results-from-the-Phase-2-201-Trial-Evaluating-Risvodetinib-for-the-Treatment-of-Parkinson-s-Disease.html

Feb 20, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next